Injectable Combination Products Of Fosaprepitant And 5-HT3 Blocker
Sterile pharmaceutical products of Fosaprepitant and a 5-HT3 blocker for parenteral administration including a container containing a formulation of Fosaprepitant or a pharmaceutically acceptable salt thereof and 5-HT3 blocker. The formulations may comprise surface-active agent and a pharmaceutically acceptable vehicle. The formulations may be lyophilized and diluted prior to administration or ready to use liquids or a pre-lyophilization solution.
1 . A liquid sterile pharmaceutical product of Fosaprepitant and a 5-HT3 blocker for parenteral administration comprising:
a container containing a liquid formulation including
Fosaprepitant or a pharmaceutically acceptable salt thereof;
5-HT3 blocker;
surface-active agent at about 0.01% to 20% w/v; and
a pharmaceutically acceptable vehicle.
2 . The product of claim 1 , wherein the surface-active agent is 0.05% to 15% w/v of the formulation.
3 . The product of claim 1 , wherein the surface-active agent is Polysorbate 80.
4 . The product of claim 1 further comprising at least one of a tonicity agent, pH adjusting agent and chelating agent.
5 . The product of claim 1 , wherein the 5-HT3 blocker is selected from the group consisting of Ondansetron, Palonosetron, Granisetron, Dolesetron, Tropisetron, and Zatisetron.
6 . The product of claim 1 , wherein the formulation comprises Fosaprepitant Dimeglumine and Palonosetron Hydrochloride.
7 . The product of claim 6 , wherein the concentration of Fosaprepitant Dimeglumine is from 0.5 mg/mL to 250 mg/mL and the concentration of Palonosetron Hydrochloride is from 1 μg/mL to 500 μg/mL.
8 . A lyophilized sterile pharmaceutical product of Fosaprepitant and 5-HT3 blocker for parenteral administration comprising:
a container containing a lyophilized powder of Fosaprepitant or a pharmaceutically acceptable salt thereof; and a 5-HT3 blocker.
9 . The product of claim 8 , wherein the 5-HT3 blocker is selected from the group consisting of Ondansetron, Palonosetron, Granisetron, Dolesetron, Tropisetron, and Zatisetron.
10 . The product of claim 9 , wherein the 5-HT3 blocker is Ondansetron or a salt thereof.
11 . The product of claim 10 , wherein the Ondansetron is Ondansetron Hydrochloride.
12 . The product of claim 8 , wherein the 5-HT3 blocker is Palonosetron or a salt thereof.
13 . The product of claim 12 , wherein the Palonosetron is Palonosetron Hydrochloride.
14 . The product of claim 8 , wherein the powder is reconstituted with a diluent to contain Fosaprepitant Dimeglumine from about 5 mg/mL to 150 mg/mL and Ondansetron HCl from about 0.5 mg/mL to 32 mg/mL for parenteral administration.
15 . The reconstituted product of claim 14 , wherein the diluent for reconstitution is water for injection, 0.9% sodium chloride injection, 5% Dextrose, a tonicity adjusting agent or any combination thereof.
16 . The reconstituted solution of claim 14 , wherein the solution is further diluted at least 5 times before parenteral administration.
17 . A pre-lyophilization solution of Fosaprepitant and 5-HT3 blocker comprising about 0.5 mg/mL to 250 mg/mL Fosaprepitant Dimeglumine and at least one of Ondansetron Hydrochloride and Palonosetron Hydrochloride.
18 . The pre-lyophilization solution of claim 17 comprising about 0.5 mg/mL to 32 mg/mL Ondansetron Hydrochloride.
19 . The pre-lyophilization solution of claim 17 comprising about 0.01 mg/mL to 0.5 mg/mL Palonosetron Hydrochloride.
20 . The pre-lyophilization solution of claim 17 , wherein the solution contains water, alcohol or a combination thereof as solvent.